ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment and biologic drugs"

  • Abstract Number: 871 • 2019 ACR/ARP Annual Meeting

    ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

    Zachary Wallace1, Huifeng Yun 2, Jeffrey Curtis 2, Shuo Yang 2, Lang Chen 2, John Stone 3 and Hyon K. Choi 4, 1Massachusetts General Hospital, Boston, 2University of Alabama at Birmingham, Birmingham, AL, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens.  As such, treatment…
  • Abstract Number: 1401 • 2019 ACR/ARP Annual Meeting

    Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis

    Ashley Fletcher 1, Marissa Lassere2, Lyn March 3, Catherine Hill 4, Claire Barrett 5, Graeme Carroll 6 and Rachelle Buchbinder 1, 1Cabrini Health/Monash University, Melbourne, Australia, 2St George Hospital, University of New South Wales, Sydney, Australia, 3University of Sydney, Sydney, Australia, 4Royal Adelaide Hospital/The University of Adelaide/The Queen Elizabeth Hospital, Adelaide, Australia, 5Redcliffe Hospital, University of Queensland, Redcliffe, Australia, 6Fiona Stanley Hospital, Perth, Australia

    Background/Purpose: To describe current biologic disease-modifying antirheumatic drug (bDMARD) treatment patterns for Australian Rheumatology Association Database (ARAD) participants with Rheumatoid Arthritis (RA) including switching and…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology